What is the 13F Pro Quality Score for ERAS?

13F Pro ranks Erasca, Inc. (ERAS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ERAS's current score at https://13fpro.ai/research/ERAS (free sign-up required for the full ranking).

Which hedge funds own the most ERAS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ERAS include Frazier Life Sciences Management, L.P., BlackRock,, VR Adviser,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ERAS as soon as new 13F filings post.

Where does 13F Pro source ERAS data?

All Erasca, Inc. fundamentals and ownership data come directly from SEC EDGAR. Erasca, Inc. files with the SEC under CIK 1761918. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ERAS in?

Erasca, Inc. (ERAS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ERAS research updated on 13F Pro?

ERAS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Erasca, Inc.(ERAS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1761918 ERAS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ERAS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Erasca, Inc. (ERAS), a Healthcare sector company. ERAS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Erasca, Inc. reports net income of $-183.4M, free cash flow of $-27.4M. Top institutional holders of ERAS by reported 13-F value include Frazier Life Sciences Management, L.P., BlackRock,, VR Adviser,, based on the most recent SEC filings. ERAS trades on the Nasdaq exchange and files with the SEC under CIK 1761918. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERAS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Erasca, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-183.4M

Free Cash Flow

Q1 2026

$-27.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+23.0% YoY

$-124.5MFY 2025

FY21 $-122.8MFY23 $-125.0MFY24 $-161.7MFY25 $-124.5M

Operating Income

+21.5% YoY

$-140.9MFY 2025

FY21 $-124.9MFY23 $-141.5MFY24 $-179.6MFY25 $-140.9M

EPS (Diluted)

+36.2% YoY

$-0.44FY 2025

FY21 $-1.85FY23 $-0.83FY24 $-0.69FY25 $-0.44

Total Assets

-21.2% YoY

$396.2MFY 2025

FY21 $501.4MFY23 $395.3MFY24 $502.5MFY25 $396.2M

Op. Cash Flow

+12.8% YoY

$-95.5MFY 2025

FY21 $-79.6MFY23 $-101.2MFY24 $-109.4MFY25 $-95.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020
Net Income	$-124.5M +23.0%	$-161.7M -29.3%	$-125.0M -1.9%	$-122.8M -20.8%	$-101.7M
Operating Income	$-140.9M +21.5%	$-179.6M -26.9%	$-141.5M -13.3%	$-124.9M -14.3%	$-109.3M
EPS (Diluted)	$-0.44 +36.2%	$-0.69 +16.9%	$-0.83 +55.1%	$-1.85	—
Total Assets	$396.2M -21.2%	$502.5M +27.1%	$395.3M -21.2%	$501.4M +301.7%	$124.8M
Operating Cash Flow	$-95.5M +12.8%	$-109.4M -8.1%	$-101.2M -27.2%	$-79.6M -143.5%	$-32.7M

AI Insight: ERAS Financial Trends

Erasca swung to a $183M net loss in Q1 2026, erasing 18 months of gradual margin improvement and equity stabilization.

• Operating loss narrowed from $68M in Q2 2024 to $33M in Q4 2025, but surged to $188M in Q1 2026.

• Equity fell from $451M (Q2 2024) to $325M (Q4 2025), then rebounded to $394M in Q1 2026 despite massive loss.

• Operating cash burn stabilized near $20–32M quarterly through Q4 2025, but worsened to $27M in Q1 2026.

⚠ Q1 2026 net loss of $183M is 5.6× larger than any prior quarter—investigate one-time charges or asset write-downs.

⚠ Equity swung up despite $183M loss, signaling potential financing or revaluation event; runway clarity needed.

AI Insight: ERAS Ratio Trends

Erasca's returns collapsed sharply in Q1 2026, with ROE plummeting to -186.5%, signaling severe operational or financial deterioration.

• ROE deteriorated from -35.8% in Q4 2025 to -186.5% in Q1 2026, the worst reading across the entire dataset.

• ROIC worsened from -40.1% in Q4 2025 to -74.5% in TTM 2026, indicating capital destruction accelerated.

• ROA declined to -60.1% in TTM 2026 from -29.4% in Q4 2025, reflecting deteriorating asset productivity.

⚠ Q1 2026 ROE spike to -186.5% suggests a large one-time charge or equity reduction; requires clarification on underlying driver.

⚠ Negative returns have persisted and worsened since Q2 2024, indicating no sustainable path to profitability yet visible.

Get alerted when ERAS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Erasca, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ERAS

Frazier Life Sciences Management, L.P.
$399.2M24,675,188 sh
BlackRock, Inc.
$326.0M20,151,406 sh
VR Adviser, LLC
$265.1M16,382,812 sh
RTW INVESTMENTS, LP
$261.4M16,157,175 sh
Vivo Capital, LLC
$196.6M12,151,480 sh
VANGUARD CAPITAL MANAGEMENT LLC
$182.0M11,249,738 sh
Siren, L.L.C.
$181.9M11,244,246 sh
Logos Global Management LP
$180.4M11,150,000 sh
Paradigm Biocapital Advisors LP
$168.2M10,392,702 sh
STATE STREET CORP
$150.5M9,300,084 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$399.2M	24,675,188
BlackRock, Inc.	$326.0M	20,151,406
VR Adviser, LLC	$265.1M	16,382,812
RTW INVESTMENTS, LP	$261.4M	16,157,175
Vivo Capital, LLC	$196.6M	12,151,480
VANGUARD CAPITAL MANAGEMENT LLC	$182.0M	11,249,738
Siren, L.L.C.	$181.9M	11,244,246
Logos Global Management LP	$180.4M	11,150,000
Paradigm Biocapital Advisors LP	$168.2M	10,392,702
STATE STREET CORP	$150.5M	9,300,084

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ERAS on your watchlist

Track score changes the day Erasca, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ERAS a good stock to buy?

13F Pro's AI-powered analysis of Erasca, Inc. (ERAS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ERAS are available on the ERAS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ERAS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ERAS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Erasca, Inc.'s investment landscape.